혈소판풍부혈장(PRP) 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Platelet Rich Plasma Market Summary

The global platelet rich plasma market size was estimated at USD 650.13 million in 2025 and is projected to reach USD 1,751.45 million by 2033, growing at a CAGR of 13.2% from 2026 to 2033. Platelet-rich plasma (PRP) usage is witnessing growth owing to the increasing participation in sporting events, leading to an increasing number of cases of sports injuries and an upsurge in cosmetic surgery.

The Platelet Rich Plasma (PRP) market is expanding steadily as clinicians and patients increasingly favor autologous, minimally invasive therapies across orthopedics, sports medicine, dermatology, aesthetics, and wound care. PRP's appeal lies in its use of a patient's own blood components, which lowers immunogenic risk and aligns with broader healthcare trends toward outpatient procedures and biologic-adjacent therapies without the complexity of cell or gene treatments. Adoption is driven by rising musculoskeletal disorders, sports injuries, age-related degeneration, and aesthetic demand, particularly in private care settings where procedural flexibility is higher.

Clinical standardization and professional guidance are playing an important role in sustaining adoption. For instance, in 2025, the American Academy of Orthopaedic Surgeons continued to reference PRP within its evidence-based discussions on tendon and joint disorders, reflecting ongoing evaluation of PRP's role in musculoskeletal care rather than dismissal as an experimental intervention. This reinforces physician confidence and supports continued procedural use, even as outcomes vary by indication and protocol.

At the same time, growth in aesthetic and dermatologic applications is reinforcing the market's diversification beyond orthopedics. For instance, in 2025, the International Society of Aesthetic Plastic Surgery highlighted PRP as one of the commonly performed non-surgical regenerative adjuncts in procedures such as facial rejuvenation and hair restoration in its global practice insights. This reflects sustained patient demand for natural, biologically derived treatments and supports recurring procedural volumes in private clinics.

Global Platelet Rich Plasma Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global platelet rich plasma (PRP) market report based on type, application, end-use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Pure PRP
• Leukocyte Rich PRP
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Orthopedics
• Sports Medicine
• Cosmetic Surgery
• Dermatology
  • Ulcer Healing
  • Venous Ulcer
  • Traumatic Ulcer
  • Diabetic Ulcer
  • Pyoderma Gangrenosum Ulcer
  • Trophic Ulcer
  • Vasculitic Ulcer
  • Others
  • Others
• Ophthalmic Surgery
• Neurosurgery
• General Surgery
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Clinics
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Applications
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Applications
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Platelet Rich Plasma (PRP) Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Reimbursement Structure

Chapter 4. Platelet Rich Plasma (PRP) Market: Type Business Analysis

• 4.1. Type Market Share, 2025 & 2033
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 4.4. Pure PRP
  • 4.4.1. Pure PRP Market, 2021 - 2033 (USD Million)
• 4.5. Leukocyte Rich PRP
  • 4.5.1. Leukocyte Rich PRP Market, 2021 - 2033 (USD Million)
• 4.6. Others
  • 4.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Platelet Rich Plasma (PRP) Market: Application Business Analysis

• 5.1. Application Market Share, 2025 & 2033
• 5.2. Application Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Orthopedics
  • 5.4.1. Orthopedics Market, 2021 - 2033 (USD Million)
• 5.5. Sports Medicine
  • 5.5.1. Sports Medicine Market, 2021 - 2033 (USD Million)
• 5.6. Cosmetic Surgery
  • 5.6.1. Cosmetic Surgery Market, 2021 - 2033 (USD Million)
• 5.7. Dermatology
  • 5.7.1. Dermatology Market, 2021 - 2033 (USD Million)
• 5.8. Ophthalmic Surgery
  • 5.8.1. Ophthalmic Surgery Market, 2021 - 2033 (USD Million)
• 5.9. Neurosurgery
  • 5.9.1. Neurosurgery Market, 2021 - 2033 (USD Million)
• 5.10. General Surgery
  • 5.10.1. General Surgery Market, 2021 - 2033 (USD Million)
• 5.11. Others
  • 5.11.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Platelet Rich Plasma (PRP) Market: End Use Business Analysis

• 6.1. End Use Market Share, 2025 & 2033
• 6.2. End Use Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals Market, 2021 - 2033 (USD Million)
• 6.5. Clinics
  • 6.5.1. Clinics Market, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Platelet Rich Plasma (PRP) Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. North America Platelet Rich Plasma (PRP) Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Structure
    • 7.4.2.5. U.S. Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Structure
    • 7.4.3.5. U.S. Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Structure
    • 7.4.4.5. Mexico Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Structure
    • 7.5.2.5. Uk Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Structure
    • 7.5.3.5. Germany Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Structure
    • 7.5.4.5. France Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Structure
    • 7.5.5.5. Italy Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Structure
    • 7.5.6.5. Spain Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Structure
    • 7.5.7.5. Denmark Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Structure
    • 7.5.8.5. Sweden Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Structure
    • 7.5.9.5. Norway Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Structure
    • 7.6.2.5. Japan Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Structure
    • 7.6.3.5. China Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Structure
    • 7.6.4.5. India Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Structure
    • 7.6.5.5. Australia Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Structure
    • 7.6.6.5. South Korea Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Structure
    • 7.6.7.5. Thailand Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Structure
    • 7.7.2.5. Japan Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Structure
    • 7.7.3.5. China Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Structure
    • 7.8.2.5. South Africa Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Structure
    • 7.8.3.5. Saudi Arabia Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Structure
    • 7.8.4.5. UAE Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Structure
    • 7.8.5.5. Kuwait Platelet Rich Plasma (PRP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Johnson & Johnson Services, Inc.
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Arthrex, Inc
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. EmCyte Corporation
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Dr PRP USA LLC
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Juventix Regenerative Medical, LLC.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Terumo Corporation
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Zimmer Biomet
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Stryker
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Apex Biologix
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Celling Biosciences, Inc
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives